Tenaya Therapeutics Q2 net loss of $23.3 narrows

Reuters

Aug 07

Tenaya <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss of $23.3 narrows

Overview

Tenaya Therapeutics Q2 net loss of $23.3 mln narrows
Co completes enrollment in key gene therapy trials, enabling dose expansion
Cash reserves expected to support operations into second half of 2026

Outlook

Tenaya anticipates TN-201 and TN-401 data readouts in Q4 2025
Company expects cash runway into second half of 2026

Result Drivers

TRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz Ali
SAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trials

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income	Beat	-$23.28 mln	-$25.90 mln (5 Analysts)
Q2 Operating Income	Beat	-$24.08 mln	-$26.30 mln (4 Analysts)
Q2 Pretax Profit	Beat	-$23.28 mln	-$25.90 mln (5 Analysts)
Q2 Basic EPS		-$0.14
Q2 Operating Expenses		$24.08 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 86.1% above its August 5 closing price of $0.70

Press Release: ID:nGNX8sTDLv

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557588722"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557588722\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557588722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557588722","market":"nz","top_or_hot":-1,"title":"Tenaya Therapeutics Q2 net loss of $23.3 narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss of $23.3 narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Tenaya Therapeutics Q2 net loss of $23.3 mln narrows</p></li><li><p>Co completes enrollment in key gene therapy trials, enabling dose expansion</p></li><li><p>Cash reserves expected to support operations into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tenaya anticipates TN-201 and TN-401 data readouts in Q4 2025</p></li><li><p>Company expects cash runway into second half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz Ali</p></li><li><p>SAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trials</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Beat</p></td><td><p>-$23.28 mln</p></td><td><p>-$25.90 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>-$24.08 mln</p></td><td><p>-$26.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$23.28 mln</p></td><td><p>-$25.90 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.14</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$24.08 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/TNYA\">Tenaya Therapeutics Inc</a> is $5.00, about 86.1% above its August 5 closing price of $0.70</p></li></ul><p>Press Release: <span>ID:nGNX8sTDLv</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Therapeutics Q2 net loss of $23.3 narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Therapeutics Q2 net loss of $23.3 narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss of $23.3 narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Tenaya Therapeutics Q2 net loss of $23.3 mln narrows</p></li><li><p>Co completes enrollment in key gene therapy trials, enabling dose expansion</p></li><li><p>Cash reserves expected to support operations into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tenaya anticipates TN-201 and TN-401 data readouts in Q4 2025</p></li><li><p>Company expects cash runway into second half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz Ali</p></li><li><p>SAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trials</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Beat</p></td><td><p>-$23.28 mln</p></td><td><p>-$25.90 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>-$24.08 mln</p></td><td><p>-$26.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$23.28 mln</p></td><td><p>-$25.90 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.14</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$24.08 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/TNYA\">Tenaya Therapeutics Inc</a> is $5.00, about 86.1% above its August 5 closing price of $0.70</p></li></ul><p>Press Release: <span>ID:nGNX8sTDLv</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX30DA13:2","article_id":"2557588722","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557588722","pubTimestamp":1754517606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tenaya Therapeutics Q2 net loss of $23.3 narrowsOverviewTenaya Therapeutics Q2 net loss of $23.3 mln narrowsCo completes enrollment in key gene therapy trials, enabling dose expansionCash reserves exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","TNYA":"Tenaya Therapeutics Inc"},"translate_title":"Tenaya Therapeutics第二季度净亏损收窄23.3美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9},"content_text":"Tenaya Therapeutics Q2 net loss of $23.3 narrowsOverviewTenaya Therapeutics Q2 net loss of $23.3 mln narrowsCo completes enrollment in key gene therapy trials, enabling dose expansionCash reserves expected to support operations into second half of 2026OutlookTenaya anticipates TN-201 and TN-401 data readouts in Q4 2025Company expects cash runway into second half of 2026Result DriversTRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz AliSAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trialsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net IncomeBeat-$23.28 mln-$25.90 mln (5 Analysts)Q2 Operating IncomeBeat-$24.08 mln-$26.30 mln (4 Analysts)Q2 Pretax ProfitBeat-$23.28 mln-$25.90 mln (5 Analysts)Q2 Basic EPS-$0.14Q2 Operating Expenses$24.08 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 86.1% above its August 5 closing price of $0.70Press Release: ID:nGNX8sTDLv(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}